SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase.
Sandra HuberTorsten HaferlachManja MeggendorferStephan HutterGregor HoermannConstance BaerWolfgang KernClaudia HaferlachPublished in: Leukemia (2022)